Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Therabel Pharma NV Holding

www.therabel.com

Latest From Therabel Pharma NV Holding

Deal Terminations Not The End Of The Road For Licensed Drugs

Post-deal termination, approximately 14% of the drugs from those alliances go on to be approved, and of those still in development, nearly two-thirds advance at least one phase. Third in a series of follow-ups to IN VIVO’s 2014 study comparing/contrasting likelihood of approval and up-front payments on alliances, and the outcomes of relevant deals.

BioPharmaceutical Deals

BioAlliance agrees $44m deal with Vestiq for miconazole

BioAlliance Pharma has entered into a licence agreement with Vestiq Pharmaceuticals, under which the latter gains the US commercialisation rights to the antifungal treatment, Oravig (miconazole), for oropharyngeal candidiasis in adults.

Infectious Diseases Cancer

Deals Shaping the Medical Industry (06/2011)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions.

Scotland accepts Roche's Mabthera but rejects its Herceptin for use on NHS

The Scottish Medicines Consortium (SMC), Scotland's health technology assessment body, has recommended Roche's Mabthera (rituximab) as a maintenance therapy for treating follicular lymphoma after induction therapy. But it has again rejected the firm's Herceptin (trastuzumab) for patients with metastatic stomach cancer.

Cardiovascular Gynecology & Urology
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Therabel Pharma NV
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Parent & Subsidiaries
  • Therabel Pharma NV Holding
  • Senior Management
  • Marco Barazzoni, CFO
    Jean-Michel Robert, Chmn.
  • Contact Info
  • Therabel Pharma NV Holding
    Phone: (31) (0)76 571 10 10
    Takkebijsters 17 sub 15
    Breda, NL-4817 BL
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register